T. Rowe Price Associates’s Inhibrx, Inc. Common Stock INBX Stock Holding History

T. Rowe Price Associates’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,812	Closed	-$518K	–	3089
2024 Q1	$518K	Buy	14,812 +1,112	+8%	+$40.6K	﹤0.01%	2196
2023 Q4	$521K	Buy	13,700 +986	+8%	+$21.1K	﹤0.01%	2151
2023 Q3	$234K	Buy	12,714 +703	+6%	+$14.7K	﹤0.01%	2447
2023 Q2	$312K	Buy	+12,011	New	+$281K	﹤0.01%	2348

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

T. Rowe Price Associates's INBX Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 14,812 shares — an estimated $518K sold.

T. Rowe Price Associates first reported a position in INBX in Q2 2023 and held it in 4 quarters. The position peaked at $521K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

T. Rowe Price Associates reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
T. Rowe Price Associates sold 14,812 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $518K.
T. Rowe Price Associates first reported a position in Inhibrx, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
T. Rowe Price Associates's Inhibrx, Inc. Common Stock position peaked at $521K in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.